Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Jasper Therapeutics to post earnings of ($1.17) per share for the quarter.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, analysts expect Jasper Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Jasper Therapeutics Price Performance
Shares of JSPR traded down $0.33 during mid-day trading on Tuesday, hitting $4.91. The stock had a trading volume of 45,730 shares, compared to its average volume of 286,838. The firm has a market cap of $73.68 million, a P/E ratio of -1.04 and a beta of 2.74. Jasper Therapeutics has a 52 week low of $3.13 and a 52 week high of $26.84. The business has a fifty day moving average price of $4.75 and a 200-day moving average price of $11.87.
Analyst Ratings Changes
A number of equities analysts have commented on JSPR shares. Royal Bank of Canada decreased their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research note on Thursday, January 9th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th. JMP Securities reissued a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $38.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $62.50.
Check Out Our Latest Research Report on JSPR
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
